Skip to main content Back to Top
Advertisement

7/1/2022

Rifampin Capsules

Products Affected - Description

    • Rifampin oral capsule, Akorn, 150 mg, bottle, 30 count, NDC 61748-0015-30
    • Rifampin oral capsule, Akorn, 300 mg, bottle, 30 count, NDC 61748-0018-30
    • Rifampin oral capsule, Akorn, 300 mg, bottle, 60 count, NDC 61748-0018-60
    • Rifampin oral capsule, Akorn, 300 mg, bottle, 100 count, NDC 61748-0018-01
    • Rifampin oral capsule, Lupin, 150 mg, bottle, 30 count, NDC 68180-0658-06
    • Rifampin oral capsule, Lupin, 300 mg, bottle, 30 count, NDC 68180-0659-06

Reason for the Shortage

    • Akorn did not provide a reason for the shortage.
    • Lupin did not provide a reason for the shortage.
    • Epic Pharma has rifampin capsules available.

Available Products

    • Rifampin oral capsule, Epic Pharma, 150 mg, bottle, 30 count, NDC 42806-0801-30
    • Rifampin oral capsule, Epic Pharma, 300 mg, bottle, 30 count, NDC 42806-0799-30
    • Rifampin oral capsule, Epic Pharma, 300 mg, bottle, 100 count, NDC 42806-0799-01

Estimated Resupply Dates

    • Akorn has rifampin 150 mg capsules in 30 count bottles, 300 mg capsules in 30 count bottles, and 300 mg capsules in 100-count bottles on allocation. The 300 mg capsules in 60-count bottles are on back order and the company estimates a release date of late-July 2022.
    • Lupin has rifampin 150 mg and 300 mg capsules on back order and the company estimates a release date of late-July 2022.

Updated

Updated July 1, 2022 by Anthony Trovato, PharmD, BCPS. Created March 14, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.